Cyclica Inc., an in silico drug discovery company, has raised $1.475 million in Series 1 Class A2 Preferred Share offering from a group of private investors (ON, BC, and USA).
Toronto based Cyclica helps pharmaceutical companies navigate the drug discovery pipeline by assessing the safety and efficacy of drugs. Cyclica’s in-house, drug-centric and structure-based bioinformatics platform, Ligand Express™ offers novel insight and analysis into a drugs’ effects.
In September 2016, Cyclica closed a $2.4 Million Series A1 financing led by GreenSky Accelerator Fund I, LP, with additional investment from both existing and new investors, including the China Canada Angel Alliance, and the family of Anthony Griffiths.